Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-251 in healthy participants
NCT07423299Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT-251 in inflammatory bowel disease (IBD) (2 arms). Primary endpoint: Number of Subjects with non-SAEs and SAEs at 14 days. Started Jan 2026; status: recruiting.
02
Drugs
MT-251
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07423299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423299.